- Home
- NTRA vs PBA Comparison
NTRA vs PBA Comparison
Compare NTRA & PBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- PBA
- Stock Information
- Founded
- NTRA 2003
- PBA 1997
- Country
- NTRA United States
- PBA Canada
- Employees
- NTRA N/A
- PBA N/A
- Industry
- NTRA Medical Specialities
- PBA Oil & Gas Production
- Sector
- NTRA Health Care
- PBA Energy
- Exchange
- NTRA Nasdaq
- PBA Nasdaq
- Market Cap
- NTRA 20.6B
- PBA 24.0B
- IPO Year
- NTRA 2015
- PBA N/A
- Fundamental
- Price
- NTRA $161.01
- PBA $36.41
- Analyst Decision
- NTRA Strong Buy
- PBA Buy
- Analyst Count
- NTRA 15
- PBA 1
- Target Price
- NTRA $152.67
- PBA $57.00
- AVG Volume (30 Days)
- NTRA 1.2M
- PBA 1.6M
- Earning Date
- NTRA 11-12-2024
- PBA 11-05-2024
- Dividend Yield
- NTRA N/A
- PBA 5.32%
- EPS Growth
- NTRA N/A
- PBA 51.43
- EPS
- NTRA N/A
- PBA 2.43
- Revenue
- NTRA $1,531,955,000.00
- PBA $7,305,229,650.00
- Revenue This Year
- NTRA $53.71
- PBA N/A
- Revenue Next Year
- NTRA $11.00
- PBA $15.54
- P/E Ratio
- NTRA N/A
- PBA $15.43
- Revenue Growth
- NTRA 54.94
- PBA 37.18
- 52 Week Low
- NTRA $58.53
- PBA $32.81
- 52 Week High
- NTRA $175.63
- PBA $43.44
- Technical
- Relative Strength Index (RSI)
- NTRA 45.49
- PBA 24.28
- Support Level
- NTRA $153.53
- PBA $35.73
- Resistance Level
- NTRA $172.80
- PBA $39.39
- Average True Range (ATR)
- NTRA 5.91
- PBA 0.63
- MACD
- NTRA -2.98
- PBA -0.35
- Stochastic Oscillator
- NTRA 8.17
- PBA 14.02
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its assets include pipelines and gas gathering as well as assets across fractionation, storage, and propane exports.